546 related articles for article (PubMed ID: 8497119)
1. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
2. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
3. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
4. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
[TBL] [Abstract][Full Text] [Related]
5. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice].
Saito H; Tomioka H; Sato K; Hidaka T
Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice].
Tomioka H; Sato K; Saito H; Hidaka T
Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070
[TBL] [Abstract][Full Text] [Related]
9. [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice].
Saito H; Murakami K; Kobayashi K; Gidoh M; Hidaka T; Kwon HH
Kekkaku; 1999 Sep; 74(9):677-81. PubMed ID: 10535281
[TBL] [Abstract][Full Text] [Related]
10. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881
[TBL] [Abstract][Full Text] [Related]
11. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
12. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of macrolide in pulmonary nontuberculous mycobacteriosis].
Tomono K
Kekkaku; 1994 Nov; 69(11):725-32. PubMed ID: 7837727
[TBL] [Abstract][Full Text] [Related]
14. [Antimycobacterial activity of a newly synthesized fluoroquinolone, Y-26611].
Tomioka H; Sato K; Saito H; Ikeda Y
Kekkaku; 1992 Jul; 67(7):515-20. PubMed ID: 1331603
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
Mizutani S
Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Saito H; Tomioka H; Sato K; Kawahara S; Hidaka T; Dekio S
Tuber Lung Dis; 1995 Feb; 76(1):51-8. PubMed ID: 7718848
[TBL] [Abstract][Full Text] [Related]
18. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex.
Hajime Saito ; Haruaki Tomioka ; Katsumasa Sato ; Satoshi Dekio
Int J Antimicrob Agents; 1994 Aug; 4(3):175-81. PubMed ID: 18611608
[TBL] [Abstract][Full Text] [Related]
20. [In vitro and in vivo activities of chemically synthesized lipid A-subunit analogue, JTP3309, against mycobacterial infections in mice and in mouse peritoneal macrophages].
Suzuki H; Saito H; Sato K; Tomioka H
Kekkaku; 1995 Apr; 70(4):285-92. PubMed ID: 7760537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
